Pinned post
Topline results studying brexu-cel in relapsed B-ALL, now out @JCO_ASCO. My thanks to @LoriMuffly and partners from 30+ centers driven to answer ?s in a rare disease space. More to come. @bshah @MoffittNews @UChicagoHemOnc
ascopubs.org/doi/10.1200/JC…
ascopubs.org Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With... PURPOSEOn the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration... ascopubs.org/doi/10.1200/JC…
